Sonnet BioTherapeutics Files to Sell 5M Shares of Common Stock for Holders
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
Minneapolis, Minnesota--(Newsfile Corp. - May 3, 2024) - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be partic
Express News | Sonnet Biotherapeutics Holdings: Post Purchase Agreement, Co Has Right From Time to Time at Option to Sell to Chardan up to Lesser of $25 Mln
Express News | Sonnet Biotherapeutics Holdings: On May 2, Entered Purchase Agreement, Registration Rights Agreement, Each With Chardan for “Chef,” Chardan’s Facility
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting Download as PDF March 19, 2024 7:30am EDT PRINCETON
RNLX, ASLN and SONN Among Pre-market Losers
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street
US equities were in red territory after Monday's opening bell as traders looked ahead to the consumer inflation report due for release later in the week for clues on the direction of the Federal Reser
Top Premarket Gainers
Kidpik Corp. (PIK) shares soared more than three-fold Monday premarket following a 5.9% gain in the previous session. The L.S. Starrett Company (SCX) shares surged 56% after the company agreed to a ta
Express News | Sonnet BioTherapeutics Shares Are Trading Higher After the Company's Phase 1b/2a Clinical Trial of SON-080 Was Cleared to Proceed to Phase 2 After Review by an Independent DSMB
Express News | Sonnet BioTherapeutics Says Early Safety Data From Phase 1b/2a Clinical Trial Of SON-080 In Chemotherapy-Induced Peripheral Neuropathy Met Study's Initial Pre-Specified Objective
Sonnet BioTherapeutics Announces Early Safety Data From the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective
Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‐080 was reviewed by the study's Data Safety Monitoring Board (DSMB)The adverse event profile and tolerability
Express News | Sonnet BioTherapeutics Reported SON-1010 Phase I Trial Results: Demonstrates Safety, Efficacy in Melanoma Model, and Potential for Dose Escalation
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today t
Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital
Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital
Chardan Cuts PT on Sonnet BioTherapeutics to $30 From $75 to Reflect Higher Projected Future Share Count, Keeps Buy Rating
Chardan Cuts PT on Sonnet BioTherapeutics to $30 From $75 to Reflect Higher Projected Future Share Count, Keeps Buy Rating.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersCogent Biosciences (NASDAQ:COGT) shares rose 45.6% to $7.95 during Wednesday's pre-market session. The company's market cap stands at $684.6 million. Lineage Cell Therapeutics (AMEX:LCTX) stock
Sonnet BioTherapeutics Q1 EPS $(0.31) May Not Be Comparable To $(0.90) Estimate, Sales $18.63K Beat $18.00K Estimate
Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.90) by 65.56 percent. This is a 98.24 percent increase over losses
Sonnet BioTherapeutics GAAP EPS of -$0.31
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
Successfully raised approximately $4.55 million in gross proceeds through an underwritten public offeringExtensive preclinical data on SON-1210 published in Frontiers in ImmunologyReceived approval and executed agreement
BTIG Reaffirms Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)
No Data